Assessment of Serum Levels of E-Selectin and L-Selectin in Alopecia Areata

Marwa Moustafa El-Ashwah 1, Abeer Hodeib 1, Hala Metwally 2 and Lamia Elgarhy 1, *

1Department of Dermatology, Faculty of Medicine, Tanta University, Tanta, Egypt
2Department of Biochemistry, Tanta University, Tanta, Egypt
*Corresponding author: Department of Dermatology, Faculty of Medicine, El Giesh St., Tanta, Egypt. Tel: +20-1069469305, Email: lamia_elgarhy@yahoo.com

Received 2019 September 02; Revised 2019 October 29; Accepted 2019 November 09.

Abstract

Background: Alopecia Areata (AA) is an immune system disease that invades anagen Hair Follicles (HFs) and shows multifactorial etiology. One of the essential histopathological features of AA is a lymphocytic intrusion that envelops HFs. Soluble forms of Endothelial (E), Lymphocytic (L), and Platelets (P)-selectins are known markers of persistent bothering. There are limited examinations for the assessment of serum levels of soluble E-selectin, L-selectin, and P-selectin in patients with AA.

Objectives: We assessed serum levels of soluble E-selectin and L-selectin in patients with in association with the control group to determine their role in the pathogenesis of the disease.

Methods: The study included 30 patients with AA and 10 healthy subjects who served as controls. Blood samples were taken from all patients and controls. The serum levels of soluble E-selectin and L-selectin were determined with the Enzyme-linked Immunosorbent Assay (ELISA) method.

Results: Higher levels of sE-selectin and sL-selectin were found in AA patients than in controls. There was a significant relationship between the higher serum levels of sE-selectin and the increased size of lesions with time. There was a significant positive correlation between the serum levels of sE-selectin and sL-selectin and the percentage of hair loss.

Conclusions: This study showed that sE-selectin and sL-selectin may play a significant role in the pathogenesis of AA and might open a way to future treatments for this disease.

Keywords: Alopecia Areata, E-selectin, P-selectin

1. Background

Alopecia Areata (AA) is a reversible, immunologically intervened disease, causing the demolition of Hair Follicles (HFs) and immediate hair loss. The disease has typical long term endless course. It essentially diminishes the patient’s personal satisfaction. The etiology and pathogenesis of the disease have not been completely explained. It has been proposed that damage to HFs happens regarding the encompassing lymphocytic penetration, which is seen in histopathologic assessment (1, 2). Another pathogenetic factor relates to blocked angiogenesis with the critical role of selectins (1, 3). Endothelial (E)-selectin is considered one of the genuine markers of endothelial cell damage, while soluble forms of E-selectin, lymphocytic (L)-selectin, and platelets (P)-selectin are considered as pointers of advancing inflammation (2). Concentration of selectins is generally assessed in psoriasis, systemic lupus erythematosus, urticaria, dermatitis, lichen planus, bullous pemphigoid, pemphigus vulgaris, scleroderma and other autoimmune diseases (4, 5). There are limited assays for the evaluation of serum concentration of soluble E-selectin, L-selectin, and P-selectin in patients with AA (6, 7).

Selectins are carbohydrate-binding particles that dilemma to fucosylated and sialylated glycoprotein ligands, and are detected on endothelial cells, leucocytes, and platelets. They has a role in attraction of cells of the innate immune system, T-lymphocytes and platelets. A non-appearance of selectins or selectin ligands has serious outcomes in mice or humans, leading to recurrent bacterial infections and persistent disease. Selectins are associated with constitutive lymphocyte homing and in the acute and chronic inflammation processes, including post-ischemic inflammation in muscles, kidneys and heart, skin inflammation, atherosclerosis, glomerulonephritis, and lupus erythematosus (8).

2. Methods

After endorsement of the research ethics committee (approval code 30807/03/16), this study was conducted as a...
case-control study on 30 patients with AA at different sites with no history of previous treatment. They were enrolled from April 2016 to January 2017 in an outpatient clinic. Patients with old AA lesions, on topical or systemic treatment, treated with antihistamines or vascular drugs in the last six months, pregnant and lactating women, and patients with autoimmune disease were excluded from the study.

In addition, 30 healthy volunteers were included as controls. Written informed consent was taken from all participants in this study. All studied subjects underwent history taking, general and dermatological examination, routine laboratory investigations, clinical assessment of AA severity by SALT score, and estimation of the serum level of sE-selectin and sL-selectin by ELISA.

The clinical assessment of AA severity by the SALT Score (9) in the scalp was done by partitioning the scalp into four quadrants and by outwardly deciding the level of scalp male pattern baldness in each quadrant and including the numbers together with a maximum score of 100%. The sores were divided as follows:

- S0 = no hair loss
- S1 ≤ 25% hair loss
- S2 = 25% - 49% hair loss
- S3 = 50% - 74% hair loss
- S4 = 75% - 95% hair loss
- S5 = 100% hair loss
- a = 75%-95% hair loss
- b = 96% - 99% hair loss
- S6 = 100% hair loss.

We collected 5 mL of venous blood from all participants under complete aseptic conditions in plain tubes. They were centrifuged and the obtained sera were isolated and stored in aliquots at -70°C until use for the estimation of serum sE-selectin and sL-selectin levels using human sE-selectin ELISA kit (Sun Red, catalog No. 201-12-0263) and human sL-selectin ELISA kit (Sun Red, catalog No. 201-12-7316).

2.1. Statistical Analysis

Data were imported to a PC and analyzed using IBM SPSS programming group variation V. 20.0. (Armonk, NY: IBM Corp) (10). Subjective data were presented as numbers and percentages. The Kolmogorov-Smirnov test was used to check the distribution of data. Quantitative data were presented as ranges (minimum and maximum), mean, standard deviation, and median. Significance of the obtained results was judged at the 5% level.

3. Results

This study enrolled 30 AA patients, including 17 males (56.67%) and 13 females (43.33%). The control group comprised 30 patients, including 21 males (70%) and 9 females (30%). The clinical data of studied patients are shown in Tables 1 and 2.

3.1. Enzyme-Linked Immune Sorbent Assay (ELISA) Results of sE-selectin and sL-selectin

There were significantly higher serum sE-selectin and sL-selectin levels in AA patients than in controls (P < 0.001). There was no significant relationship between the serum level of sE-selectin and sex, age, special habits, presence of stress, past history, family history, or nail involvement in the patient group. There was a significant relationship between the higher serum level of sE-selectin and the number of hair loss patches (P = 0.001). No significant relationship was reported between the serum level of sE-selectin and the site of hair loss and the size of each patch in the patient group. There was a significant relationship between the higher serum levels of sE-selectin and the increased size of lesions with time (P = 0.004). There was no significant relationship between the serum level of sE-selectin and SALT score (P = 0.089).

There was a significant positive correlation between the serum level of sE-selectin and the percentage of hair loss (r = 0.661 and P < 0.001) (Figure 1). There was a significant positive correlation between the level of sE-selectin and the number of hair loss patches (r = 0.625 and P < 0.001).

There was no significant relationship between the serum level of sL-selectin and sex, age, special habits, presence of stress, past history, family history, or nail involvement in the patient group. No significant relationship was detected between the serum level of sL-selectin and the number of patches, the site of hair loss, the size of patches, changes in the size of the lesions with time, and the SALT score in the patient group.

There was a significant positive correlation between the serum level of sL-selectin and the size of hair loss patches (r = 0.370 and P = 0.044). There was a significant positive correlation between the serum level of sL-selectin and the percentage of scalp hair loss (r = 0.518 and P = 0.007) (Figure 2).

There was no significant relationship between the serum level of sE-selectin and the serum level of sL-selectin in the patient group.

Figure 1. Correlation between sE-selectin and percentage of hair loss in the patient group
Table 1. Demographic Data of Studied Groups

|                      | Patients (N = 30) | Controls (N = 30) | Test of Sig. | P Value |
|----------------------|-------------------|-------------------|--------------|---------|
| Sex                  |                   |                   | χ² = 0.556² | 0.71³   |
| Male, no. (%)        | 17 (56.67)        | 21 (70)           |              |         |
| Female, no. (%)      | 13 (43.33)        | 9 (30)            |              |         |
| Male:female ratio    | 1.33              | 2.33              |              |         |
| Age, y               |                   |                   | t = 0.865⁵  | 0.39³   |
| Min. - max.          | 3 - 60            | 6 - 56            |              |         |
| Mean ± SD            | 22.07 ± 17.06     | 27.30 ± 14.90     |              |         |
| Median               | 19                | 26.50             |              |         |

¹ Chi-square test for comparing the two groups.
² P value for Monte Carlo for chi-square test to compare the two groups.
³ t and P values for Paired t-test to compare the two groups.

4. Discussion

Alopecia areata is a typical, clinically heterogenous, insusceptible intervened, non-scaring hair loss (11, 12). It is a chronic disease mediated by T lymphocytes with a multifactorial pathogenesis. The histological assessment of AA injury uncovers cell penetration around HFs with a large number of T-cells and other provocative cells (13). Cormia and Ernyey in 1961 (14) reported bald skin the presence of inflammatory infiltrate around blood vessels with a thickening of their walls. Endothelial-selectin plays a significant role in managing T-lymphocytes to the inflammation sites (15-17). It is additionally a ligand of antigens found on the outside of fiery cells, including Cutaneous Lymphocyte-related Antigen (CLA). Patients with severe AA demonstrate significantly higher CLA-positivity in peripheral blood lymphocytes, CD4+, and CD8+ lymphocytes than normal controls. Also, the penetration of CLA-positive lymphocytes around HFs of patients with AA was shown by immuno-histochemistry. These outcomes propose that most lymphocytes penetrating around HFs of AA patients are CLA-positive T-lymphocytes (16).

Lymphocytic-selectin is found on the outside of lymphocytes, granulocytes, and monocytes (18). Its appearance decreases after cell activation. The inflammatory mediators peel of L-selectin from leucocyte cell surface which leads to the increase its soluble forms (19). Soluble forms of this molecule are probably capable of inhibiting the adhesion processes (19).

The present study showed significantly higher serum levels of sE-selectin and sL-selectin in AA patients than in controls. The results of the study were supported by a recent study in which Sudnik et al. (6) reported significantly higher E-selectin serum levels in patients with AA than in healthy controls. They explained that the raised levels were due to the scaling of E-selectin from the outside of endothelial cells. This may indicate a progressing fiery procedure in the vessels (6).

In this investigation, there was a huge distinction in the concentration of sE-selectin due to the disease, with higher values in the active phase. This was in the concurrence with the result by Sudnik et al. (6) who detected a higher concentration of sE-selectin in the active phase of the disease. These findings show that E-selectin plays a critical part in the advancement of the disease and it might be an indicator of severe AA.

The present study demonstrated a statistically significant increase in the concentration of serum sE-selectin with multiple patches of AA. There was a positive correlation between the serum level of sE-selectin and the percentage of the area of hair loss. This result was in agreement with Sudnik et al. (6) who identified an elevated normal concentration of sE-selectin in patients with progressively severe AA, which might be related to the severity of lymphocytic penetration in different types of AA.

Leeuwenberg et al. (20) demonstrated sE-selectin secreted by activated endothelial cells identified with sand-
Table 2. Distribution of Studied Patients According to Size of Lesion, Changes with Time, Body Hair Loss, and SALT Score

| Values |
|--------|
| **Size (cm²)** |
| < 2 | 6 (20) |
| 2 - 5 | 21 (70) |
| > 5 | 3 (10) |
| Min. - max. | 1 - 8 |
| Mean ± SD | 2.97 ± 1.77 |
| Median | 2.50 |
| **Size change with time** |
| No change | 14 (46.67) |
| Decrease | - |
| Increase | 16 (53.33) |
| **Nail involvement** |
| -ve | 25 (83.33) |
| +ve | 5 (16.67) |
| **Body hair loss** |
| B0 | 26 (86.67) |
| B1 | 4 (13.33) |
| **SALT** |
| S1 | 23 (76.67) |
| S2 | 3 (10) |
| S3 | - |
| S4 | - |
| S5 | - |
| **Percentage** |
| Min. - max. | 1 - 30 |
| Mean ± SD | 7.54 ± 8.98 |
| Median | 2 |

*Values are expressed as No. (%), unless it was mentioned (N = 30).*

wich ELISA. According to the increase of E-selectin expression in the scalp, it may lead to the increased release of E-selectin from activated endothelial cells because E-selectin gene transcription is strongly downregulated within 6 to 9 hours after induction (21). E-selectin mRNA has a short half-life and E-selectin is quickly disguised and degraded in lysosomes (21). Previous studies showed that a little part of the total E-selectin expressed on endothelial cell surface is released (20, 22). The mechanisms controlling its release have not been clarified. Soluble E-selectin has been in use for well over 10 years as a marker of endothelial cell activation or irritation that may associates with the seriousness of illness or outcome (23, 24). Another study showed a high expression of E-selectin in a patient with 14 years’ history of AA in contrast with psoriatic skin (25).

The current study also demonstrated a positive correlation between the serum level of sL-selectin and the percentage of the area of hair loss and the size of lesion. The expression of L-selectin identified on the surface of lymphocytes, granulocytes, and monocytes is diminished after cell activation (18). The inflammatory mediators peel of L-selectin from leucocyte cell surface that leads to increase its soluble form (19, 26). Soluble forms of L-selectin are most likely fit for repressing the adhesion processes (27).

In agreement with Sudnik et al. (6), there was no huge difference in the convergence of s-L-selectin depending on the movement of the illness. However, the participation of adhesion molecules in inflammation is a self-limiting process. It is known that interaction of selectins, both soluble and associated with the cell membrane forms, can affect the activity of the inflammatory process. It is acknowledged that the serum type of L-selectin is apparently a fragment of the cradle framework, which confines the path toward moving leucocytes and henceforth their migration to destinations of irritation (28). Elevated levels of s-L-selectins in patients with AA, as reported in the present study, can likewise restrain the relocation of leucocytes to destinations of aggravation. It appears that the evaluation of articulation of these selectins in the skin of AA patients would be gainful.

A shown in this study, the increased serum levels of s-E-selectin and s-L-selectin in patients with AA may indicate the possible role of s-E-selectin and s-L-selectin in the pathogenesis of AA. In this unique situation and given the difficulties in the treatment of AA, the probability of commencement of treatment planned for repressing the activity of selectins, including E-selectin, should be considered.

**Footnotes**

**Conflict of Interests:** No conflict of interest is reported.

**Ethical Approval:** The approval code was 30807/03/16.

**Funding/Support:** No funding or support is reported.

**References**

1. Gilhar A, Kalish RS. Alopecia areata: A tissue specific autoimmune disease of the hair follicle. *Autoimmun Rev.* 2006;5(1):64–9. doi: 10.1016/j.autrev.2005.07.001. [PubMed: 16338213].
2. Wang E, McElwee KJ. Etiopathogenesis of alopecia areata: Why do our patients get it? *Dermatol Ther.* 2011;24(3):337–47. doi: 10.1111/j.1529-8019.2011.01416.x. [PubMed: 21689243].
3. Varricchi G, Granata F, Loffredo S, Genovese A, Marone G. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. *J Am Acad Dermatol.* 2015;73(1):144–53. doi: 10.1016/j.jaad.2015.03.041. [PubMed: 25922287].
4. Groves RW, Kapahi P, Barker JN, Haskard DO, MacDonald DM. Detection of circulating adhesion molecules in erythrodermic skin disease. *J Am Acad Dermatol.* 1995;33(2):32–6. doi: 10.1016/0190-9622(95)90880-9. [PubMed: 7529777].
5. Ciolkiewicz M, Kuryliszyn-Moskal A, Klimiuk PA. Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients. Clin Rheumatol. 2010;29(2):375-80. doi: 10.1007/s10067-009-1087-7. [PubMed: 19907904].

6. Sudnik W, Danczak-Pazdrowska A, Silny W, Osmola-Mankowska A, Pazdrowski J, Polanska A. The role of selectins in alopecia areata. Postepy Dermatol Alergor. 2015;32(1):27-32. doi: 10.5134/pd.2014.40946. [PubMed: 25821424]. [PubMed Central: PMC4160002].

7. Nickoloff BJ, Griffiths CE. Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. J Invest Dermatol. 1999;113(5):915-25. doi: 10.1111/j.1523-1747.ep2472216. [PubMed: 1708803].

8. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6):283-8. doi: 10.1016/S1471-4914(01)00076-5. [PubMed: 12829015].

9. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield EA, Hordinsky MK. Overview of alopecia areata. J Am Acad Dermatol. 2003;48(1):15-27. doi: 10.1061/jaad.2003.09.032. [PubMed: 15337988].

10. Kirkpatrick IA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Belmont, California: Wadsworth, Cengage Learning; 2013. 1 p.

11. Hordinsky MK. Overview of alopecia areata. J Invest Dermatol. 2004;31(3):440-7. doi: 10.1016/j.jaad.2003.09.032. [PubMed: 15337988].

12. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood. 1996;88(9):3259-77. [PubMed: 899639].

13. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield EA, Hordinsky MK. Overview of alopecia areata. J Am Acad Dermatol. 2003;48(1):15-27. doi: 10.1016/j.jaad.2003.09.032. [PubMed: 15337988].

14. Cormia FE, Ernyey A. Circulatory changes in alopecia. Preliminary report, with a summary of the cutaneous circulation of the normal scalp. Arch Dermatol. 1961;84:772-89. doi: 10.1001/archderm.1961.0158070066009. [PubMed: 13881352].

15. Yano S, Nakamura K, Okochi H, Tamaki K. Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. Acta Derm Venereol. 2002;82(2):82-5. doi: 10.1080/00015550252948077. [PubMed: 12125957].

16. Lacueva L, Guilabet A, Ferrando J. The expression of cutaneous lymphocyte-associated antigen (CLA) in alopecia areata. Eur J Dermatol. 2005;15(3):201-2. [PubMed: 15937755].

17. Wedepohl S, Beceren-Braun F, Riese S, Buscher K, Enders S, Bernhard G, et al. L-selectin—a dynamic regulator of leukocyte migration. J Exp Biol. 2012;215(1):257-64. doi: 10.1016/j.jeb.2011.02.007. [PubMed: 21540194].

18. Spertini O, Schleiffenbaum B, White-Owen C, Ruiz P Jr, Tedder TF. ELISA for quantitation of L-selectin shed from leukocytes in vivo. J Immunol Methods. 1992;156(1):115-23. doi: 10.1016/0021-9953(92)90017-n. [PubMed: 1385536].

19. Leeuwenberg Jr, Smets EF, Neeles J, Shaffer MA, Cinek T, Jeun-homme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77(4):541-9. [PubMed: 1285598]. [PubMed Central: PMC1421640].

20. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 2005;320(3):584-9. doi: 10.1016/j.bbrc.2004.09.002. [PubMed: 15824252].

21. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood. 1996;88(9):3259-77. [PubMed: 899639]